Soleno Therapeutics Ownership
| SLNO Stock | USD 58.34 1.12 1.96% |
Shares in Circulation | First Issued 2013-03-31 | Previous Quarter 38.6 M | Current Value 41.9 M | Avarage Shares Outstanding 5.8 M | Quarterly Volatility 10.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Soleno |
Soleno Stock Ownership Analysis
About 97.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.79. Soleno Therapeutics last dividend was issued on the 6th of October 2017. The entity had 1:15 split on the 26th of August 2022. Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California. Soleno Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people. To find out more about Soleno Therapeutics contact Anish MD at 650 213 8444 or learn more at https://soleno.life.Besides selling stocks to institutional investors, Soleno Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Soleno Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Soleno Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Soleno Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Soleno Therapeutics Insider Trades History
Roughly 3.0% of Soleno Therapeutics are currently held by insiders. Unlike Soleno Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Soleno Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Soleno Therapeutics' insider trades
Soleno Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Soleno Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Soleno Therapeutics backward and forwards among themselves. Soleno Therapeutics' institutional investor refers to the entity that pools money to purchase Soleno Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-06-30 | 1 M | Alyeska Investment Group, L.p. | 2024-09-30 | 976.1 K | Fmr Inc | 2024-09-30 | 665.4 K | Holocene Advisors, Lp | 2024-09-30 | 594.4 K | Sofinnova Ventures | 2024-06-30 | 554.4 K | Tcg Crossover Management, Llc | 2024-09-30 | 550 K | Geode Capital Management, Llc | 2024-09-30 | 540.3 K | Samlyn Capital, Llc | 2024-09-30 | 511.8 K | Westfield Capital Management Company, Lp | 2024-09-30 | 495.7 K | Vivo Capital, Llc | 2024-09-30 | 6.3 M | The Carlyle Group Inc | 2024-09-30 | 4.1 M |
Soleno Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Soleno Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Soleno Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Soleno Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Soleno Therapeutics Outstanding Bonds
Soleno Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Soleno Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Soleno bonds can be classified according to their maturity, which is the date when Soleno Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Soleno Therapeutics Corporate Filings
8K | 26th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 19th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Pair Trading with Soleno Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Soleno Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Soleno Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Soleno Stock
| 0.83 | MTEM | Molecular Templates | PairCorr |
| 0.71 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.71 | AGL | agilon health | PairCorr |
| 0.69 | VALN | Valneva SE ADR | PairCorr |
| 0.67 | NKTX | Nkarta Inc | PairCorr |
The ability to find closely correlated positions to Soleno Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Soleno Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Soleno Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Soleno Therapeutics to buy it.
The correlation of Soleno Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Soleno Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Soleno Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Soleno Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.79) | Return On Assets (0.48) | Return On Equity (0.91) |
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.